XNAS · Healthcare · Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
BioLine Rx posted a mixed Q2: **$0.00 EPS** beat by **$0.24**, but revenue of **$294k** missed expectations and slipped slightly year over year. For a tiny biotech, the lack of top-line momentum and no new catalyst keeps the update weak despite the accounting-driven earnings improvement.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | Q2 2026 | -0.24 | 0.00 | +100.00% | $294,000 | ✅ Beat | +4.62% | — | — |
| 2026-05-27 | Q1 2026 | -1.04 | 0.00 | +100.00% | $477,000 | ✅ Beat | +2.85% | -2.67% | -6.08% |
| 2026-03-23 |
| Q4 2025 |
| -0.54 |
| -0.34 |
| +37.04% |
| $194,000 |
| ✅ Beat |
| +3.77% |
| -3.02% |
| -3.45% |
| 2025-11-24 | Q3 2025 | -0.49 | -0.22 | +55.10% | $427,000 | ✅ Beat | — | — | — |
| 2025-08-14 | Q2 2025 | -0.46 | -1.00 | -117.39% | $304,000 | ❌ Miss | — | — | — |
| 2025-05-27 | Q1 2025 | -1.06 | 0.00 | +100.09% | $255,000 | ✅ Beat | — | — | — |
| 2025-03-31 | Q4 2024 | 0.00 | 0.00 | — | $11.7M | ➖ Inline | — | — | — |
| 2024-11-25 | Q3 2024 | -0.10 | -0.07 | +30.00% | $4.9M | ✅ Beat | — | — | — |
Showing last 8 quarters.